+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
MOREPENLAB

Morepen Laboratories Share Price

₹126.00 +2.46 (1.99%)
281.24% Gain from 52W Low

26 Oct, 2026 10:20 AM (IST)

Morepen Laboratories live price: ₹126.00. It opened at ₹123 vs previous close ₹124; intraday high/low: ₹128/₹119. The 50 & 200 DMA stand at ₹111.80/₹75.80.

Morepen Laboratories Performance

  • Today's Low
  • ₹119
  • Today's High
  • ₹128
  • 52 Week Low
  • ₹33
  • 52 Week High
  • ₹151
  • Open Price₹123
  • Previous Close₹124
  • Volume2,338,479
  • 50 DMA₹111.80
  • 100 DMA₹93.60
  • 200 DMA₹75.80

Morepen Laboratories Chart

Investment Returns

  • Over 1 Month + 4.67%
  • Over 3 Month + 134.2%
  • Over 6 Month + 202.01%
  • Over 1 Year + 157.99%

Smart Investing Starts Here Start SIP with Morepen Laboratories for Steady Growth!

Invest Now

Morepen Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 49.1
  • PEG Ratio
  • 0.9
  • Market Cap Cr
  • 6,904
  • P/B Ratio
  • 5.3
  • Average True Range
  • 8.6
  • EPS
  • 2.6
  • Dividend Yield
  • 0.2
  • MACD Signal
  • 2
  • RSI
  • 51.83
  • MFI
  • 51.94

Latest Stock News Updates

Morepen Laboratories Ltd - 500288 - Board Meeting Intimation for Q-2 FY27 Financial Results

Morepen Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 ,inter alia, to consider and approve financial results for the quarter and half year ended 30 September 2026

Morepen Laboratories Ltd - 500288 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Please find attached the disclosure

Morepen Laboratories files its first US ANDA for sitagliptin tablets

The filing for sitagliptin tablets in three strengths marks Morepen's entry into integrated finished-dose development and regulatory filings in the US market

Morepen Laboratories Financials

Morepen Laboratories Technicals

EMA & SMA

Current Price
₹126.00
+ 2.46 (1.99%)
pointer
  • Bearish Moving Average 1
  • Bullish Moving Average 15
  • 20 Day
  • ₹123.50
  • 50 Day
  • ₹111.80
  • 100 Day
  • ₹93.60
  • 200 Day
  • ₹75.80

Resistance and Support

124.3 Pivot Speed
  • R3 137.60
  • R2 130.60
  • R1 127.10
  • S1 116.50
  • S2 109.50
  • S3 106.00

Morepen Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-10-27 Quarterly Results
2026-08-04 Quarterly Results
2026-05-26 Audited Results & Final Dividend (Revised)
2026-02-10 Quarterly Results
2025-11-14 Quarterly Results
Date Purpose Remarks
2026-09-19 FINAL Rs.0.20 per share(10%)Final Dividend
2025-08-30 FINAL Rs.0.20 per share(10%)Final Dividend
View Morepen Laboratories Dividend History Arrow
Date Purpose Remarks
2000-11-22 Split

Morepen Laboratories Shareholding Pattern

59.19%
35.65%
3.43%
1.71%

About Morepen Laboratories

Morepen Laboratories engaged with the medical fraternity and the wider public on matters of everyday health. Leveraging the leadership position of Saltum, the No. 1 brand in its category in the Indian pharmaceutical market, the Company conducted a dedicated campaign during Antimicrobial Resistance (AMR) Awareness Week to reinforce responsible antibiotic use among physicians and patients. View More
  • NSE Symbol
  • MOREPENLAB
  • BSE Symbol
  • 500288
  • ISIN
  • INE083A01026

Similar Stocks to Morepen Laboratories

Morepen Laboratories FAQs

Morepen Laboratories share price is ₹126 As on 26 October, 2026 | 10:10

The Market Cap of Morepen Laboratories is ₹6904.2 Cr As on 26 October, 2026 | 10:10

The P/E ratio of Morepen Laboratories is 49.1 As on 26 October, 2026 | 10:10

The PB ratio of Morepen Laboratories is 5.3 As on 26 October, 2026 | 10:10

The 52 week High & Low of Morepen Laboratories is ₹150.7/₹33 respectively As on 26 October, 2026 | 10:10

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23